GlassScriptPhysician profile
Stephen W Thompson
NPI 1316934433
$2,647.91
in general payments reported to CMS, 2019-2025
37 companies · $21.30 in 2025
The $21.30 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $352 · 2021: $986 · 2022: $360 · 2023: $691 · 2025: $21.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.26 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.26 | 2020-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Pfizer INC. | $291.56 | 2019-2023 | |
| Therapeuticsmd, INC. | $247.13 | 2019-2022 | |
| Exeltis, USA INC. | $220.76 | 2020-2023 | Slynd |
| Mayne Pharma Commercial LLC | $142.31 | 2021-2023 | |
| Baxter Healthcare | $121.34 | 2021 | |
| Merck Sharp & Dohme LLC | $100.99 | 2019-2023 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $97.54 | 2023 | Myfembree |
| Lupin INC. | $81.34 | 2020-2021 | |
| Organon LLC | $65.72 | 2021-2023 | Nexplanon |
| Evofem Biosciences, INC. | $63.76 | 2021-2022 | |
| Avion Pharmaceuticals | $57.71 | 2021-2023 | Balcoltra |
| Currax Pharmaceuticals LLC | $57.33 | 2020-2023 | Contrave |
| Millicent US INC | $52.66 | 2020 | |
| Myovant Sciences INC. | $50.09 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.71 | 2020-2021 | |
| Novo Nordisk INC | $46.92 | 2019-2021 | |
| Hologic Sales and Service, LLC | $45.85 | 2019-2021 | |
| Exact Sciences Corporation | $43.73 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $35.49 | 2022-2023 | Quviviq |
| Agile Therapeutics, INC. | $33.37 | 2021 | |
| Amag Pharmaceuticals, INC. | $29.44 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.58 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.30 | 2025 | Jynarque |
| Daiichi Sankyo INC. | $18.89 | 2021 | |
| Astellas Pharma US INC | $18.30 | 2020 | |
| Coopersurgical, INC. | $17.09 | 2019 | |
| Shield Therapeutics INC | $16.61 | 2023 | Accrufer |
| Nestle Healthcare Nutrition INC. | $15.05 | 2022 | |
| Duchesnay USA Incorporated | $14.34 | 2019 | |
| Dysis Medical, INC. | $13.93 | 2022 | |
| Allergan, INC. | $13.91 | 2020 | |
| Caldera Medical, INC | $13.22 | 2021 | |
| Alydia Health | $13.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.87 | 2019 | |
| Amgen INC. | $12.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.